the potential for both companies would seem great in wound care , but the execution , product , R&D, are all quite distinguishable so much so that the brain gets scrambled trying to compare.
But I think the greatest difference is the strategy. PNV strategy seems to have been driven/influenced by its gross margin on the existing product , whereas ARX has been product development.
hence the seemingly huge disparity in value
Come on finish 1.60 plus, page-345
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
0.020(3.17%) |
Mkt cap ! $224.1M | |||
| Open | High | Low | Value | Volume |
| 62.0¢ | 65.0¢ | 61.5¢ | $322.3K | 516.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 172966 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| ARX (ASX) Chart |